242 related articles for article (PubMed ID: 3361077)
1. Criteria for the cure of acromegaly: comparison between basal growth hormone and somatomedin C plasma concentrations in active and non-active acromegalic patients.
Giannella-Neto D; Wajchenberg BL; Mendonça BB; Almeida SF; Macchione M; Spencer EM
J Endocrinol Invest; 1988 Jan; 11(1):57-60. PubMed ID: 3361077
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the criteria for assessing the outcome of treatment in acromegaly.
Lindholm J; Giwercman B; Giwercman A; Astrup J; Bjerre P; Skakkebaek NE
Clin Endocrinol (Oxf); 1987 Nov; 27(5):553-62. PubMed ID: 3450453
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly.
Losa M; Oeckler R; Schopohl J; Müller OA; Alba-Lopez J; von Werder K
J Neurosurg; 1989 Apr; 70(4):561-7. PubMed ID: 2647918
[TBL] [Abstract][Full Text] [Related]
4. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
5. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.
Barkan AL; Beitins IZ; Kelch RP
J Clin Endocrinol Metab; 1988 Jul; 67(1):69-73. PubMed ID: 2897974
[TBL] [Abstract][Full Text] [Related]
6. Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly.
de la Piedra C; Larrañaga J; Castro N; Horcajada C; Rapado A; Herrera Pombo JL; Carbó E
Calcif Tissue Int; 1988 Jul; 43(1):44-5. PubMed ID: 3145120
[TBL] [Abstract][Full Text] [Related]
7. Somatomedin-C in active and successfully treated acromegaly.
Knappe G; Hesse V; Jahreis G; Rohde W; Gerl H
Exp Clin Endocrinol; 1988 Mar; 91(1):2-6. PubMed ID: 3371416
[TBL] [Abstract][Full Text] [Related]
8. Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response.
Stonesifer LD; Jordan RM; Kohler PO
J Clin Endocrinol Metab; 1981 Nov; 53(5):931-4. PubMed ID: 7197287
[TBL] [Abstract][Full Text] [Related]
9. Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with sandostatin (SMS 201-995).
Lamberts SW; Uitterlinden P; Verleun T
Eur J Clin Invest; 1987 Aug; 17(4):354-9. PubMed ID: 2889603
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly.
Barreca A; Ciccarelli E; Minuto F; Bruzzi P; Giordano G; Camanni F
Acta Endocrinol (Copenh); 1989 May; 120(5):629-35. PubMed ID: 2728807
[TBL] [Abstract][Full Text] [Related]
11. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
12. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.
Giusti M; Lomeo A; Monachesi M; Mazzocchi G; Attanasio R; Sessarego P; Mignone D; Del Monte P; Giordano G
J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356
[TBL] [Abstract][Full Text] [Related]
13. Discrepancies between bioassayable somatomedin activity and somatomedin C levels in acromegalic patients.
Jasper HG; Artese R; Molocznik I; Bruno O
Medicina (B Aires); 1986; 46(4):440-4. PubMed ID: 3574106
[No Abstract] [Full Text] [Related]
14. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
Losa M; Schopohl J; König A; Müller OA; von Werder K
J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between clinical and endocrinological features following transsphenoidal surgery of acromegaly. With special reference to somatomedin-C level].
Osawa M; Kobayashi S; Takemae T; Nakagawa F
Neurol Med Chir (Tokyo); 1988 Mar; 28(3):254-8. PubMed ID: 2457827
[No Abstract] [Full Text] [Related]
18. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
19. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
Levitt NS; Ratanjee BD; Abrahamson MJ
Horm Metab Res; 1995 Apr; 27(4):185-8. PubMed ID: 7750902
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of insulin-like growth factor (somatomedin) levels in acromegaly.
Rieu M
Horm Res; 1986; 24(2-3):112-5. PubMed ID: 3530936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
